Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

Slides:

Advertisements

Similar presentations

Barriers to Participation in Clinical Trials Pediatric Oncology

Advertisements

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Advancing the Development of Pediatric Therapeutics II: Evaluation of Long-term Neurocognitive Development in Pediatrics Lynne P. Yao, M.D. Acting Director,

Daniel J. Isaacman, m.D., FAAP

Risk Communication Advisory Committee Risk Communication Issues in the Food and Drug Administration Amendments Act of 2007 February 28, 2008.

SUBPART D PRESENTATION Inaugural meeting of the Pediatric Ethics Subcommittee (PES) of the Pediatric Advisory Committee (PAC); part of the inaugural meeting.

Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Clinical Trials Registry Susan Koenig, MPP&PA Director, Office of Compliance & Quality University of Missouri-Columbia School of Medicine Compliance &

Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.

Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.

HIV Drug Development in Neonates - What Now? Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products FDA.

11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.

What FDA Failed to Disclose 1991, 2006 Vera Hassner Sharav Alliance for Human Research Protection.

Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 

Special Issues in FDA-Regulated Studies: The Good, the Bad, and the Ugly C. Karen Jeans, MSN, CCRN, CIP COACH Program Analyst VA Office of Research & Development.

Yesterday, today, and tomorrow

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

International Human Subject Research Legal and Ethical Considerations for Investigators Theresa J. Colecchia, Esq. Associate General Counsel May 8, 2006.

Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.

Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.

PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee Meeting September 15, 2004

Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

Overview of FDA's Regulatory Framework for PET Drugs

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Europe & USA: Interactions on Pediatric Clinical Trials

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

History of Pediatric Labeling

The Best Pharmaceuticals for Children Act Anne Zajicek, M.D., Pharm.D. Pediatric Medical Officer National Institute of Child Health and Human Development.

Inclusion of Women in Clinical Trials & Drug Development Regulatory Perspective Ameeta Parekh, Ph.D. R&D Director Office of Women’s Health Food & Drug.

Joint NDAC/DODAC Advisory Committee Meeting March 24, 2005 Rx Topical Corticosteroids and Testing for Adrenal Suppression Markham C. Luke, M.D., Ph.D.

Pediatric Oncology and the Best Pharmaceuticals for Children Act Lisa L. Mathis, M.D. OND Associate Director Pediatric and Maternal Health Staff Office.

1 Ethical Concerns in Pediatric Placebo-controlled Trials from the European Experience Ethics of Placebo-controlled Trials in Children FDA Pediatric Advisory.

FDAAA – Report on DTC Advertising Kristin Davis, J.D. Deputy Director, Division of Drug Marketing, Advertising, and Communications Office of Medical Policy,

$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.

Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.

February 2, 2004 Pediatric Drug Development: A Decade of Progress: Susan K. Cummins, MD, MPH Medical Team Leader Division of Pediatric Drug Development.

FDA Standards Development and Implementation Randy Levin, M.D. Director, Office of Information Management Center for Drug Evaluation and Research Food.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Update on Current FDA Labeling Initiatives Iris P. Masucci, PharmD, BCPS Center for Drug Evaluation and Research FDA November 16, 2006 Pediatric Advisory.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Initiatives Drive Pediatric Drug Development January 30, 2002.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee July 15, 2003 Steven Hirschfeld, MD PhD CAPT USPHS Division of Oncology Drug.

Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 3 Drug Regulation, Development, Names, and Information.

Pediatric Drug Development: A Regulatory Perspective Tiffany R. Farchione, M.D. Medical Officer, Division of Psychiatry Products US Food and Drug Administration.

The Newborn Health Initiative

Lessons Learned from the Mistakes of Others

Patient Involvement in the Development and Safe Use of

Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.

Pediatric Clinical investigator training workshop

Pediatric Therapeutics Still working to get it right for kids

Pediatric Drug Development A Regulatory Perspective

Presentation transcript:

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation and Research February 2, 2004 Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation and Research February 2, 2004

2 Goals Provide condensed historical background to better understand how we arrived at the present place in pediatric drug development Provide condensed historical background to better understand how we arrived at the present place in pediatric drug development Review FDA’s Pediatric Drug Development responsibilities Review FDA’s Pediatric Drug Development responsibilities

3 Acronyms FDAMA – Food and Drug Administration Modernization Act FDAMA – Food and Drug Administration Modernization Act BPCA – Best Pharmaceuticals for Children Act BPCA – Best Pharmaceuticals for Children Act PREA – Pediatric Research Equity Act PREA – Pediatric Research Equity Act WR – Written Request (FDA issues) WR – Written Request (FDA issues) PPSR – Proposed Pediatric Study Request (sponsor submits) PPSR – Proposed Pediatric Study Request (sponsor submits)

4 Historical Perspective Tragedies in children lead to new laws Tragedies in children lead to new laws Biologics Control Act Biologics Control Act –diphtheria antitoxin contaminated with live tetanus bacilli Food, Drug and Cosmetic Act Food, Drug and Cosmetic Act –sulfanilamide Amendments Amendments –thalidomide

5 BENCHMARKS Pediatric Drug Development 1977 – AAP statement concerning the need to conduct trials in children 1977 – AAP statement concerning the need to conduct trials in children 1979 – FDA requires trials in children parallel to adult process 1979 – FDA requires trials in children parallel to adult process 1994 – FDA requires sponsors to update label; introduces “extrapolations” 1994 – FDA requires sponsors to update label; introduces “extrapolations” 1997 – Congress passes FDAMA/Exclusivity Provision – “Incentives” (voluntary) 1997 – Congress passes FDAMA/Exclusivity Provision – “Incentives” (voluntary) 1998 – FDA publishes Pediatric Rule (mandatory) 1998 – FDA publishes Pediatric Rule (mandatory)

6 BENCHMARKS Pediatric Drug Development (cont.) 2002 – Congress passes Best Pharmaceuticals for Children Act (BPCA) 2002 – Congress passes Best Pharmaceuticals for Children Act (BPCA) – renewed Exclusivity – provides process for “off-patent” drug development – public posting of results – reporting of all AE’s for 1 year after Exclusivity granted 2003 – Congress passes Pediatric Research Equity Act (PREA) 2003 – Congress passes Pediatric Research Equity Act (PREA) –Requires the study of drugs and biologics for pediatric population except in defined situations –Creates Pediatric Advisory Committee

7 Impact of Legislation Proposals from Industry336 Proposals from Industry336 FDA-issued Written Requests283 FDA-issued Written Requests283 Exclusivity Determinations101 Exclusivity Determinations101 Exclusivity Granted91 Exclusivity Granted91 New Labels63 New Labels63

8 1-Year Post-Exclusivity Reporting of Adverse Events Tamoxifen Tamoxifen Quinapril Quinapril Paroxetine Paroxetine Nefazodone Nefazodone Citalopram Citalopram Pravastatin Pravastatin Vinorelbine Vinorelbine Sertraline Sertraline Oxybutynin Oxybutynin Atorvastatin Atorvastatin Simvastatin Simvastatin Busulfan Busulfan Cetirizine Cetirizine Losartan Losartan Products

9 Ethical Issues Pediatric Advisory Subcommittee Meetings have addressed: Pediatric Advisory Subcommittee Meetings have addressed: –Patients vs. subjects in pediatric trials (11/15/99) –Placebo controlled trials (9/11/00) –Vulnerable pediatric populations (4/24/01)

10 Prior Peds Advisory Subcommittee Discussion 1999 November: Issues regarding a Pediatric Drug Development Program for the Treatment of Insomnia November: Issues regarding a Pediatric Drug Development Program for the Treatment of Insomnia2000 September: Pediatric Psychotropic Drug Use Issues September: Pediatric Psychotropic Drug Use Issues2001 April: Treatment of Chronic Hepatitis C in Children April: Treatment of Chronic Hepatitis C in Children2002 June: Reflux disease; GERD-Template June: Reflux disease; GERD-Template

11 Prior Peds Advisory Subcommittee Discussion (cont.) 2003 March: Development of Antiretroviral Drugs in HIV-Infected and HIV-Exposed Neonates Younger than four weeks of age March: Development of Antiretroviral Drugs in HIV-Infected and HIV-Exposed Neonates Younger than four weeks of age June: Current Epidemiology and Therapeutic Interventions Relevant to Hyperbilirubinemia in the Term and Near-Term Newborn June: Current Epidemiology and Therapeutic Interventions Relevant to Hyperbilirubinemia in the Term and Near-Term Newborn October: Clinical Risk Management of HPA Axis Suppression in Children with Atopic Dermatitis being treated with Topical Corticosteroids October: Clinical Risk Management of HPA Axis Suppression in Children with Atopic Dermatitis being treated with Topical Corticosteroids Tracking Cancer Risk among Children with Atopic Dermatitis who are treated with Topical Calcineurin Inhibitors

12 ONGOING LESSONS LEARNED 1-Pharmacokinetics are more variable than anticipated 2-Adverse reactions that are pediatric specific are being defined 3-Trial designs are being modified as we learn from submitted studies 4-Ethical issues have to be reassessed from the pediatric perspective

13 General Principles* Pediatric patients should be given medicines that have been properly evaluated for their use in the intended population Pediatric patients should be given medicines that have been properly evaluated for their use in the intended population Product development programs should include pediatric studies when pediatric use is anticipated Product development programs should include pediatric studies when pediatric use is anticipated Pediatric development should not delay adult studies nor adult availability Pediatric development should not delay adult studies nor adult availability Shared responsibility among companies, regulatory authorities, health professionals, and society as a whole Shared responsibility among companies, regulatory authorities, health professionals, and society as a whole * from ICH E-11

14 To Find out More Internet: Internet: Peds Line: Peds Line: (301) (301)